| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4459 | 2013 |
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in … MEH Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ... Journal of Clinical Oncology 28 (16), 2784-2795, 2010 | 3975 | 2010 |
| Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer JM Harvey, GM Clark, CK Osborne, DC Allred Journal of clinical oncology 17 (5), 1474-1474, 1999 | 2554 | 1999 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2291 | 2015 |
| Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy X Li, MT Lewis, J Huang, C Gutierrez, CK Osborne, MF Wu, ... Journal of the National Cancer Institute 100 (9), 672-679, 2008 | 2210 | 2008 |
| Tamoxifen in the treatment of breast cancer CK Osborne New England Journal of Medicine 339 (22), 1609-1618, 1998 | 1737 | 1998 |
| Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a … KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, ... The lancet oncology 11 (1), 55-65, 2010 | 1623 | 2010 |
| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer J Shou, S Massarweh, CK Osborne, AE Wakeling, S Ali, H Weiss, R Schiff Journal of the National Cancer Institute 96 (12), 926-935, 2004 | 1513 | 2004 |
| Diseases of the Breast JR Harris, ME Lippman, CK Osborne, M Morrow Lippincott Williams & Wilkins, 2012 | 1267 | 2012 |
| Treatment of HER2-positive breast cancer: current status and future perspectives CL Arteaga, MX Sliwkowski, CK Osborne, EA Perez, F Puglisi, L Gianni Nature reviews Clinical oncology 9 (1), 16-32, 2012 | 1092 | 2012 |
| Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer JC Chang, EC Wooten, A Tsimelzon, SG Hilsenbeck, MC Gutierrez, ... The Lancet 362 (9381), 362-369, 2003 | 1067 | 2003 |
| Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases VJ Bardou, G Arpino, RM Elledge, CK Osborne, GM Clark Journal of clinical oncology 21 (10), 1973-1979, 2003 | 1053 | 2003 |
| Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer CK Osborne, V Bardou, TA Hopp, GC Chamness, SG Hilsenbeck, ... Journal of the National Cancer Institute 95 (5), 353-361, 2003 | 1040 | 2003 |
| The value of estrogen and progesterone receptors in the treatment of breast cancer CK Osborne, MG Yochmowitz, WA Knight III, WL McGuire Cancer 46 (S12), 2884-2888, 1980 | 986 | 1980 |
| Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu CC Benz, GK Scott, JC Sarup, RM Johnson, D Tripathy, E Coronado, ... Breast cancer research and treatment 24, 85-95, 1992 | 975 | 1992 |
| Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer DC Allred, GM Clark, R Elledge, SAW Fuqua, RW Brown, GC Chamness, ... JNCI: Journal of the National Cancer Institute 85 (3), 200-206, 1993 | 960 | 1993 |
| Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes RM Lavinsky, K Jepsen, T Heinzel, J Torchia, TM Mullen, R Schiff, ... Proceedings of the National Academy of Sciences 95 (6), 2920-2925, 1998 | 882 | 1998 |
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance G Arpino, L Wiechmann, CK Osborne, R Schiff Endocrine reviews 29 (2), 217-233, 2008 | 666 | 2008 |
| Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ... Journal of the National Cancer Institute 97 (17), 1254-1261, 2005 | 647 | 2005 |
| Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy X Cui, R Schiff, G Arpino, CK Osborne, AV Lee Journal of clinical oncology 23 (30), 7721-7735, 2005 | 644 | 2005 |
